DarioHealth (DRIO) Stock Sees Fair Value Cut As Analysts Weigh Growth And Revenue Risks

DarioHealth is back in focus after an analyst fair value estimate shifted from US$15.25 to about US$12.33, a reduction of a little over 19% that resets expectations around the stock. Recent research blends optimism about the digital health platform and its multi condition offering with concerns about softer revenues, business mix changes, and execution risk, which helps explain the lower price target range. As you read on, you will see how these moving pieces fit together and how to track the evolving analyst narrative around DarioHealth.

Stay updated as the Fair Value for DarioHealth shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on DarioHealth.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Alliance Global sees DarioHealth as a vertically integrated health intelligence platform that is used to support improved health outcomes, and it assigns a US$12 price target that reflects confidence in the business model.

• BTIG highlights DarioHealth as a multi condition, vertically integrated digital health platform with what it calls robust clinical solutions in diabetes, cardiometabolic health and obesity, and it initiates coverage with a US$6 price target.

• BTIG also points to what it describes as good core growth in the B2B2C business, suggesting to investors that headline figures may not fully capture this part of the story.

• Alliance Global references potential EBITDA positive operations in 2028, which frames DarioHealth as a company some analysts view on a multi year path toward improved profitability.

🐻 Bearish Takeaways

• TD Cowen cut its DarioHealth price target from US$11 to US$8 and keeps a Hold rating after softer Q2 revenues, signaling caution around the current revenue profile.

• BTIG flags that reported growth has been affected by a deliberate move away from the bio pharma business and the loss of a large Twill account, which adds execution and concentration risk to the story.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 3 risks for DarioHealth. See which could impact your investment.

How This Changes the Fair Value For DarioHealth

• Fair value estimate moved from US$15.25 to about US$12.33, a reduction of a little over 19%.

• Forecast revenue growth rate shifted from about 38.87% to about 29.78%.

• Assumed net profit margin moved from about 6.69% to about 7.14%.

• Future P/E assumption changed from about 42.0x to about 60.6x.

• Applied discount rate moved from 9.33% to about 10.29%.